PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) Receives Average Rating of “Buy” from Analysts

Shares of PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) have been given an average rating of “Buy” by the eight research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $13.00.

PHAS has been the topic of several analyst reports. Zacks Investment Research lowered PhaseBio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 12th. Needham & Company LLC assumed coverage on PhaseBio Pharmaceuticals in a report on Thursday, May 28th. They set a “buy” rating and a $18.00 target price on the stock. Stifel Nicolaus restated a “buy” rating and set a $4.00 price objective on shares of PhaseBio Pharmaceuticals in a research report on Tuesday, May 5th. ValuEngine upgraded PhaseBio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 17th. Finally, Citigroup upped their price objective on PhaseBio Pharmaceuticals from $11.00 to $12.00 in a research report on Friday, May 29th.

Shares of PHAS traded down $0.16 during trading hours on Friday, hitting $4.39. 464,353 shares of the company were exchanged, compared to its average volume of 353,470. The company has a market cap of $130.95 million, a price-to-earnings ratio of -2.68 and a beta of 1.93. PhaseBio Pharmaceuticals has a fifty-two week low of $2.60 and a fifty-two week high of $13.95. The company has a quick ratio of 9.68, a current ratio of 9.68 and a debt-to-equity ratio of 0.23. The firm’s fifty day moving average is $4.86 and its 200 day moving average is $4.62.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.10). The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.38 million. PhaseBio Pharmaceuticals had a negative return on equity of 70.50% and a negative net margin of 2,310.60%. Analysts anticipate that PhaseBio Pharmaceuticals will post -2.04 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN raised its position in PhaseBio Pharmaceuticals by 107.0% in the first quarter. Wells Fargo & Company MN now owns 16,832 shares of the company’s stock valued at $55,000 after purchasing an additional 8,699 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new position in PhaseBio Pharmaceuticals in the fourth quarter valued at about $67,000. UBS Group AG raised its position in PhaseBio Pharmaceuticals by 39.8% in the fourth quarter. UBS Group AG now owns 18,059 shares of the company’s stock valued at $110,000 after purchasing an additional 5,139 shares during the last quarter. Barclays PLC raised its position in PhaseBio Pharmaceuticals by 41.1% in the fourth quarter. Barclays PLC now owns 21,969 shares of the company’s stock valued at $134,000 after purchasing an additional 6,403 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in PhaseBio Pharmaceuticals by 16.1% in the first quarter. Bank of New York Mellon Corp now owns 41,251 shares of the company’s stock valued at $136,000 after purchasing an additional 5,732 shares during the last quarter. Hedge funds and other institutional investors own 64.35% of the company’s stock.

PhaseBio Pharmaceuticals Company Profile

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

See Also: Penny Stocks, Risk and Reward Factors

Analyst Recommendations for PhaseBio Pharmaceuticals (NASDAQ:PHAS)

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.